Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 20/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927764 | 0.87 | ESR2 (0.77) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3925338 | 0.85 | ESR2 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL9622923 | 0.84 | ESR1 (0.72) | ESR1ESR2 | |
| SCHEMBL3933985 | 0.82 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL15892261 | 0.82 | ESR1 (0.70) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3925608 | 0.82 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3933955 | 0.80 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3933745 | 0.79 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3922766 | 0.79 | ESR2 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3928809 | 0.78 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119024654-A | Method for forming pattern | 三星SDI株式会社 | 2024-11-26 | — | — | CN | claimed |
| CN-118963076-A | Composition, method of forming pattern, and system for forming pattern | 三星SDI株式会社 | 2024-11-15 | — | — | CN | claimed |
| CN-118444539-A | Metal-containing photoresist developer composition and method of forming a pattern comprising a step of developing using the composition | 三星SDI株式会社 | 2024-08-06 | — | — | CN | claimed |
| CN-117597628-A | Method for forming pattern | 三星SDI株式会社 | 2024-02-23 | — | — | CN | claimed |
| CN-117348341-A | Metal-containing photoresist developer composition and pattern forming method | 三星SDI株式会社 | 2024-01-05 | — | — | CN | claimed |
| WO-2023003215-A1 | METHOD OF FORMING PATTERNS | 삼성에스디아이 주식회사 | 2023-01-26 | — | — | WO | claimed |
| CN-113557239-A | Oligosaccharide formulations and compositions | 米德瑞美国有限公司 | 2021-10-26 | — | — | CN | claimed |
| CN-110072949-B | Weather resistance improver, resin composition for coating metal nanowire layer, and metal-nanowire-containing laminate | 星光PMC株式会社 | 2021-05-14 | — | — | CN | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| EP-1824478-A2 | NOVEL USES FOR ESTROGEN BETA AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2006065968-A2 | THE USES OF ESTROGEN BETA AGONISTS TO TREAT COGNITIVE DISEASES | WYETH (US) | 2006-06-22 | — | — | WO | claimed |
| US-20060135574-A1 | Novel uses for estrogen beta agonists | WYETH (US) | 2006-06-22 | — | — | US | claimed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | claimed |
| US-6914074-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2005-07-05 | — | — | US | claimed |
| EP-1453782-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-08 | — | — | EP | claimed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | claimed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | claimed |
| CN-119604295-A | Use of oligosaccharide preparations to reduce the effects of necrotic enteritis in birds | 帝斯曼知识产权资产管理有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-0871454-A1 | PHOSPHOROUS-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997003679-A1 | PHOSPHOROUS-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | ESR1 2/4885ESR2 1/4885HSD17B1 160/4885 |
| US-20060135574-A1 | Novel uses for estrogen beta agonists | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885HSD17B1 99/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR1 4/4885ESR2 5/4885HSD17B1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.